Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762 
Richard Sebastian Receives Seven Generation Award at BizConn Alliance 2025
Award Recognizes Lifelong Leadership and Commitment to Advancing Native BusinessMASHANTUCKET, Conn., Nov. 28, 2025 /PRNewswire/ -- Command Holdings, a Pequot...
CIVIE Showcases Intelligent Radiology Ecosystem and RadPod at RSNA 2025
AI-powered platform brings unified workflow demos, on-demand reading capabilities, and exclusive RSNA activations to Booth #5560 in the AI ShowcaseDALLAS,...
HZICC：Unlocked potential: why global innovators choose Hangzhou
HANGZHOU, China, Nov. 28, 2025 /PRNewswire/ -- Meng Jintao, winner of the 2024 Hangzhou's Innovation & Entrepreneurship Competition for Overseas...
Tiger BioSciences Highlights Key Findings from Study on Multi-Layer Placental Allografts
CONSHOHOCKEN, Pa., Nov. 28, 2025 /PRNewswire/ -- Tiger BioSciences is drawing attention to a foundational study that continues to shape...
From Playgrounds to Patient Care: How DaVita Helps Strengthen Communities
NORTHAMPTON, MA / ACCESS Newswire / November 28, 2025 / DaVitaEarlier this year, more than 100 DaVita teammates (employees) from...
Cercare Medical Showcases Breakthrough CBCT Perfusion Technology at RSNA 2025
Bringing Advanced Perfusion Imaging Into the Angio Suite to Transform Stroke and Oncology Care CHICAGO, IL / ACCESS Newswire /...
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol “GRDX”
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that...
Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company...
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and...
Hydreight Technologies Acquires 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase up to 40%, and Establishes Strategic Partnership
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Nov. 28,...
Boehringer Ingelheim announces appointment to Board of Managing Directors
Harsha Deshmukh Harsha Deshmukh Harsha Deshmukh has been appointed a member of the Board of Managing Directors with responsibility for...
Profound Medical to Launch AI-Powered BPH Module, Present New TULSA-PRO® Clinical Data, at RSNA and SUO Meetings
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for...
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Fireside chat scheduled for Tuesday, December 2, 2025 at 12:30 PM ETNEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- TG...
Kane Biotech Announces Third Quarter 2025 Financial Results
WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced...
SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...
Shriners Hospitals for Children Canada and Children’s Hospital at LHSC launch landmark research program to advance care in rare childhood bone disorders
One-year anniversary of affiliation marked by national expansion in research and care for kids with complex conditionsMONTREAL and LONDON, Ontario,...
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”),...
Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer
Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK)...
InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis
BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the...
Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...